About The Study: Ceperognastat, a novel, orally available, small-molecule inhibitor of O -linked N -acetylglucosaminidase, did not slow disease progression of early symptomatic Alzheimer disease.
Corresponding Author: To contact the corresponding author, Adam S. Fleisher, MD, email afleisher@lilly.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.12768)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being published to coincide with the Alzheimer’s Association International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.12768?guestAccessKey=c0bca90d-cce8-4e0b-abc8-d83fddff8aa9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071326
JAMA